Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Clinical & Translational Immunology|January 1, 2020
A potential association between IL-3 and type I and III interferons in systemic lupus erythematosusShereen Oon, Katherine Monaghan, Milica Ng, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2011
Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositisLara J Herrero, Michelle Nelson, Anon Srikiatkhachorn, et al.
Rheumatology (Oxford, England)|March 18, 2022
Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosusSharzad Emamikia, Shereen Oon, Alvaro Gomez, et al.
The American Journal of Pathology|June 25, 2004
The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemiaLaveena Sharma, Els Melis, Michael J Hickey, et al.
Seminars in Arthritis and Rheumatism|September 26, 2022
Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysisTina Ko, Rachel Koelmeyer, Ning Li, et al.
RMD Open|August 21, 2023
Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysisEric Morand, Josef S Smolen, Michelle Petri, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2016
Glucocorticoid-Induced Leucine Zipper Protein Controls Macropinocytosis in Dendritic CellsJoseph Calmette, Matthieu Bertrand, Mathias Vétillard, et al.
Annals of the Rheumatic Diseases|February 2, 2025
Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controlsZahi Touma, Ian N Bruce, Richard Furie, et al.
Critical Care Explorations|June 29, 2022
Lung Ultrasound to Assist ICU Admission Decision-Making Process of COVID-19 Patients With Acute Respiratory FailureAmazigh Aguersif, Benjamine Sarton, Sihem Bouharaoua, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled TrialEric Morand, Marilyn Pike, Joan T Merrill, et al.
Pageof 8